

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**VOLUNTARY ANNOUNCEMENT
LETTER OF INTENT IN RELATION TO
LONG-TERM VACCINE MANUFACTURING CONTRACT**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that on May 20, 2019, its wholly owned subsidiary, WuXi Biologics Investments Limited, entered into a letter of intent (the “**Letter of Intent**”) with a global vaccine leader (“**Vaccine Partner**”), pursuant to which the Company will, through a company to be established by it and Shanghai Hile Bio-pharmaceutical Co., Ltd. (上海海利生物技術股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 603718) (“**WuXi Vaccines**”), build an integrated vaccine manufacturing facility, including drug substance manufacturing (DS), drug product manufacturing (DP) as well as Quality Control labs (QC), and manufacture certain vaccine for Vaccine Partner. It is expected that the manufacturing contract will be for an initial term of twenty years with a total contract value of over US\$3 billion. The parties will further negotiate in good faith with an aim to agreeing on the definitive agreements for the transactions.

Further announcement(s) will be made by the Company as and when required.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, May 20, 2019

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*